Anne Borgman, M.D.   |   Director

Dr. Borgman is the Chief Medical Officer of Sutro BioPharma, and also serves on the boards of directors of Curis and Nikang Therapeutics.  Previously, she was Vice President and Global Therapeutic Area Lead, Hematology-Oncology, at Jazz Pharmaceuticals, where she was responsible for global development of the company’s oncology and hematology drugs, including four marketed products. Previously, Dr. Borgman was Vice President, Clinical Research & Development, at Exelixis, where she was a Clinical Lead in the global development for cabozantinib in oncology indications including renal cell, hepatocellular and thyroid carcinoma. Earlier she was Chief Medical Officer and Vice President of Hana Biosciences (Talon Therapeutics), where she oversaw all aspects of the company’s drug development operations. In addition, Dr. Borgman has worked as Associate Chief Medical Officer at KaloBios Pharmaceuticals, and she was formerly a Global Development Head at Abbott Pharmaceuticals (now AbbVie) where she was responsible for the early drug development of the PARP inhibitor, antimitotic, and Bcl-2/Bcl-XL platforms. Dr. Borgman also served as a Consulting Associate Professor at Stanford University School of Medicine’s Stem Cell Transplant & Cell Biology program, and as a Clinical Associate at University of Chicago’s Department of Pediatric Oncology and Stem Cell Research. Dr. Borgman completed her fellowship in pediatric hematology – oncology and stem cell transplant at UCLA David Geffen School of Medicine, trained in pediatrics at Texas Children’s Hospital, Baylor College of Medicine, and earned her M.D. from Loyola University of Chicago’s Stritch School of Medicine. Dr. Borgman joined our company’s board of directors in October 2021.

• David Kabakoff, Ph.D. Chairman • Michael Richman Director • Elaine V. Jones, Ph.D. Director • John G. Houston, Ph.D. Director • Stephen Webster Director • Ellen G. Feigal, M.D. Director • Anne Borgman, M.D. Director